References
- Anagnostis P, Vaitsi K, Mintziori G, et al. Non-coronary atherosclerotic cardiovascular disease in patient with familial hypercholesterolaemia. Curr Med Res Opin. 2020;36:731–740.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
- Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381:1557–1567.
- Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272.
- Ridker PM, Revkin P, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
- Schwartz GG, Steg M, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
- Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PSCK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915–11920.
- Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase substilisin/kexin type 9(PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60–68.
- Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.
- Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients with high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–1440.
- Raal FJ, Kallend D, Kausik KR, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–1530.
- Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–1519.
- ClinicalTrials.gov An extension trial of inclisiran compared to evolocumab in participants with cardiovascular disease and high cholesterol. [cited 2020 May 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03060577
- FDAAA TrialsTracker NCT03060577: an overdue trial by The Medicines Company. [cited 2020 May 29]. Available from: http://fdaaa.trialstracker.net/trial/NCT03060577/
- ClinicalTrials.gov A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). [cited 2020 May 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03705234?term=ORION+inclisiran&draw=2&rank=1
- Cannon CP, Blazing MA, Guigliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med. 2015;372:2387–2397.
- Hagiwara N, Kawada-Watanabe E, Koyonagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomised trial. Eur Heart J. 2017;38:2264–2275.
- Preiss D, Tobert JA, Hovingh GK, et al. Lipid-modifying agents, from statins to PCSK9 inhibitors. J Am Coll Cardiol. 2020;75:1945–1955.
- Rymer JA, Mues KE, Monda KL, et al. Use of low-density lipoprotein-lowering therapies before and after PCSK9 inhibitor initiation. J Am Heart Assoc. 2020;9:e014347.
- Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins; a systematic review. J Clin Lipidol. 2010;4:462–471.
- Hines DM, Rane P, Patel J, et al. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409–418.
- Arrieta A, Page TF, Valedar E, et al. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One. 2017;12:e0169761.
- Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2:1217–1225.
- Novartis. Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death. [cited 2020 May 5]. Available from: https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global
- Gov.uk. New heart disease drug to be made available for NHS patients. [cited 2020 May 5]. Available from: https://www.gov.uk/government/news/new-heart-disease-drug-to-be-made-available-for-nhs-patients